Toward gaining insights into the therapeutic potential of IDO inhibitors such as navoximod alone or in combination with checkpoint inhibition and, if warranted, supporting the development of new broad spectrum checkpoint inhibition algorithms, pharmaceutical formulations that improve their tumor bioavailabilities are needed. Here, IDO1 is linked to neoplasm.